Back to top

A Phase II trial designed to evaluate the rectal safety, drug absorption and acceptability of a reduced glycerin formulation of tenofovir gel, as well as oral Truvada, at sites in Peru, South Africa, Thailand and the U.S., including Puerto Rico. The study enrolled 195 men who have sex with men (MSM) and transgender women. Results, which were reported February 2016, found the gel was safe to use, with participants preferring to use the gel around the time of sex compared to daily use.


International Study Finds High Levels of Adherence to Use of Rectal Microbicide Gel



International Study Finds Rectal Microbicide Gel Safe When Used Daily and With Sex



MTN-017 Backgrounder



MTN-017 Q&A



See Also

VIDEO – The Rectal Revolution is Here


Rectal Microbicides – Fact Sheet



Other Study Milestones

Researchers Launch First-Ever Phase II Safety Study of a Rectal Microbicide to Prevent HIV



MTN and Partners Launch “The Rectal Revolution Is Here: An Introduction to Rectal Microbicide Clinical Trials”



Gel Safe and Acceptable as Approach to Preventing HIV from Anal Sex in Early Phase Clinical Trial



Reduced Glycerin Formulation of Tenofovir Vaginal Gel Safe for Rectal Use



Rectal Formulation of Tenofovir Gel Found Safe and Acceptable in Early Phase Clinical Study



See Also

MTN-017 Study Protocol and MTN-017 Letter of Amendment